Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2003-01-14
2008-12-23
Kim, Jennifer (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S381000, C514S561000, C514S563000
Reexamination Certificate
active
07468390
ABSTRACT:
The invention relates a pharmaceutical composition comprising a combination of:(i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction, such as Alzheimer's, glaucoma and stroke, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof.
REFERENCES:
patent: 4610816 (1986-09-01), Berger
patent: 4722810 (1988-02-01), Delaney et al.
patent: 4740499 (1988-04-01), Olins
patent: 4749688 (1988-06-01), Haslanger et al.
patent: 4929641 (1990-05-01), Haslanger et al.
patent: 5217996 (1993-06-01), Ksander
patent: 5223516 (1993-06-01), Delaney et al.
patent: 5273990 (1993-12-01), De Lombaert
patent: 5294632 (1994-03-01), Erion et al.
patent: 5399578 (1995-03-01), Buhlmayer et al.
patent: 5520522 (1996-05-01), Rathore et al.
patent: 0 342 850 (1989-11-01), None
patent: 0 343 911 (1989-11-01), None
patent: 0 361 365 (1990-04-01), None
patent: 0 443 983 (1991-08-01), None
patent: 0 498 361 (1992-08-01), None
patent: 0 636 621 (1995-02-01), None
patent: 0 726 072 (1996-08-01), None
patent: 0636621 (1997-03-01), None
patent: 2 218 983 (1989-11-01), None
patent: WO 90/09374 (1990-08-01), None
patent: WO 92/14706 (1992-09-01), None
patent: WO 93/09101 (1993-05-01), None
patent: WO 93/10773 (1993-06-01), None
patent: WO 94/15908 (1994-07-01), None
patent: WO 01/74348 (2001-10-01), None
patent: WO 02/06253 (2002-01-01), None
patent: WO 02/092622 (2002-11-01), None
patent: WO 03/066606 (2003-08-01), None
Almeida et al., “Clearance Function of Type C Receptors of Atrial Natriuretic Factor in Rats”,Am J Physiol, vol. 256, pp. R469-R475 (1989).
Bazil, Krulan and Webb, “Telemetric Monitoring of Cardiovascular Parameteres in Conscious Spontaneously Hypertensive Rats”,J Cardiovasc Pharmacol, vol. 22, pp. 897-905 (1993).
Consensus Trial Study Group, “Effects of Enalapril on Mortality in Severe Congestive Heart Failure”,N Eng J Med, vol. 316, No. 23, pp. 1429-1435 (1987).
Stephenson et al., The hydrolysis of a-human atrial natriuretic peptide by pig kindney microvillar membranes is initiated by endopeptidase-24.11Biochem J, vol. 243, pp. 183-187(1987).
Erdös, “Angiotensin I Converting Enzyme and the Changes in Our Concepts Through the Years”—Lewis K. Dahl Memorial Lecture,Hypertension, vol. 16, No. 4, pp. 363-370 (1990).
Intengan, Park and Schiffrin, “Blood Pressure and Small Arteries in DOCA-Salt-Treated Genetically AVP-Deficient Rats”,Hypertension, vol. 34, No. 4, Part 2, pp. 907-913 (1999).
Intengan, Thibault, Li and Schiffrin, “Resistance Artery Mechanics, Structure, and Extracellular Components in Spontaneously Hypertensive Rats”,Circulation, vol. 100, No. 22, pp. 2267-2275 (1999).
Needleman et al., “Biochemical Pharmacology of Atrial Peptides”,Annu Rev Pharm Tox, vol. 29, pp. 23-54 (1989).
Stephenson and Kenny, “Metabolism of Neuropeptides”,Biochem J, vol. 241, pp. 237-247 (1987).
Sybertz et al., “SCH 39370, a Neutral Metalloendopeptidase Inhibitor, Potentiates Biological Responses to Atrial Natriuretic Factor and Lowers Blood Pressure in Desoxycorticosterone Acetate-Sodium Hypertensive Rats”,J Pharmacol Exp Ther, vol. 250, No. 2, pp. 624-631 (1989).
Sybertz et al., “Atrial Natriuretic Factor-Potentiating and Antihypertensive Activity of SCH 34826”,Hypertension, vol. 15, No. 2, pp. 152-161 (1990).
Williford, Sharma, Korth and Sheu, “Spatial Heterogeneity of Intracellular Ca2+Concentration in Nonbeating Guinea Pig Ventricular Myocytes”,Circ Res, vol. 66, No. 1, pp. 241-249 (1990).
Zannad, “The Emerging Role of ACE Inhibitors in the Treatment of Cardiovascular Disease”,J Cardiovasc Pharmacol, vol. 15, Suppl. 2, pp. S1, S5 (1990).
Caplus Abstract AN 1986:573042—Taub et al., f ZA8400670, Sep. 25, 1985.
Caplus Abstract AN 1995: 931230- Sugano et al., JP 07157459, Jun. 20, 1995.
Caplus Abstract AN 1995:412660—Yamada et al., JP 06234754, Aug. 23, 1994.
Matsumoto et al., “Blockade of renin-angiotensin system and enhancement of atrial natriuretic peptide with neutral endopeptidase inhibition cause natriuresis in congestive heart failure and renal dysfunction in conscious dogs”, JASN, Hemodynamics and Vascular Regulation, p. 517, Sep. 1993).
Ksander Gary Michael
Webb Randy Lee
Ferraro Gregory D.
Kim Jennifer
Novartis AG
LandOfFree
Methods of treatment and pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment and pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment and pharmaceutical composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4050342